In mammals, myosin light chain kinase (MLCK) is encoded by the *mylk1* and *mylk2* genes ([@B19]). *mylk2* encodes an MLCK isoform that is exclusively expressed in skeletal muscle cells ([@B19]; [@B55]). Because of the lack of data on *mylk2* gene coding products, we mainly discuss *mylk1* gene products, which include long chain MLCK (220 kDa), short chain MLCK (130 kDa), and the non-catalytic carboxy-terminal (17 kDa) protein, telokin ([@B11]; [@B8]; [@B3]). *mylk1* gene coding products are expressed in diverse cell types and tissues including muscle, platelets, and secretory and brain cells ([@B26]). Numerous cell activities, such as contraction, adhesion, cell migration, and epithelial barrier formation occur in a myosin regulatory light chain (MLC) phosphorylation dependent or independent manner ([@B11]; [@B8]; [@B28]). Abnormal expression of MLCK has been observed in many inflammatory diseases including pancreatitis ([@B47]), respiratory diseases ([@B75]), cardiovascular diseases ([@B14]), cancer ([@B74]), and inflammatory bowel disease (IBD) ([@B68]). The involvement of MLCK and the MLCK signaling pathway that underlie representative inflammatory diseases is discussed. Some diseases in which MLCK is involved are listed in **Table [1](#T1){ref-type="table"}**.

###### 

Role of myosin light chain kinase (MLCK) in selected diseases.

  Diseases                                           MLCK changes                         MLCK isoform   Representative References
  -------------------------------------------------- ------------------------------------ -------------- ---------------------------
  Atherosclerosis                                    Increased expression                 nmMLCK         [@B76]
  Hypertension                                       Increased activity                   smMLCK         [@B15]
  Heart injury/Heart failure                         Increased activity                   Cardiac MLCK   [@B32]; [@B6]
  Glaucoma                                           Increased activity                   smMLCK         [@B41]
  Asthma                                             Increased expression/Gene variant    nmMLCK         [@B75]
  Lung inflammation/Lung injury                      Increased expression /Gene variant   nmMLCK         [@B36]; [@B63]
  Brain injury /Kidney injury                        Increased expression                 nmMLCK         [@B66]; [@B16]
  Intestinal inflammation /IBD/Barrier dysfunction   Increased expression                 nmMLCK         [@B17]; [@B25]; [@B64]
  Intestinal motility disorder                       Increased/Decreased expression       smMLCK         [@B9]
  Pancreatitis                                       Increased                            nmMLCK         [@B47]
  Prostate Cancer                                    --                                   nmMLCK         [@B49]
  Breast cancer                                      --                                   nmMLCK         [@B28]
  Pancreatic cancer                                  --                                   nmMLCK         [@B27]
  Non-small cell lung cancer                         Increased                            nmMLCK         [@B35]
  Cervical cancer                                    --                                   nmMLCK         [@B46]
  Gastric cancer                                     --                                   nmMLCK         [@B13]

nmMLCK, non-muscle MLCK; smMLCK, smooth muscle MLCK

.

MLCK in Respiratory Diseases, Atherosclerosis, and Pancreatitis
===============================================================

In inflammatory lung disorders, damage to lung endothelial cell barrier integrity alters vascular permeability, and alveolar flooding often results ([@B34]). Abnormal expression of MLCK occurs in lung injury, and the MLCK inhibitor ML-7 or deletion of the *MLCK* gene can attenuate lung injury ([@B56]). MLCK has similar activity in asthmatic and in lung inflammation, and variation of the *MYLK* gene is strongly associated with acute lung injury and asthma susceptibility ([@B57], [@B58]; [@B56]).

MLCK-induced endothelial barrier dysfunction is also involved in pancreatitis and atherosclerosis ([@B14]; [@B57]; [@B56]). Severe acute pancreatitis is associated with high morbidity and mortality. Its pathogenesis is not completely understood ([@B71]), but MLCK expression is significantly increased in rat models of acute pancreatitis ([@B47]), and elevation of tumor necrosis factor (TNF)-α in severe acute pancreatitis has been shown to mediate MLCK-dependent regulation of the cytoskeleton, leading to destruction of the endothelial barrier function ([@B47]; [@B70]). The initiation and development of atherosclerosis often leads to progressive vascular injury, which is accompanied by endothelial dysfunction ([@B40]). The involvement of MLCK in the natural history of atherosclerosis has been confirmed by alleviation of vascular injury and atherosclerosis by ML-7, an MLCK inhibitor ([@B14]).

MLCK in Cancer Development
==========================

Abnormal expression of MLCK has been observed in pancreatic, lung, and prostate cancer cell lines ([@B53]; [@B37]; [@B12]). Rapid, dynamic changes of the cytoskeleton are needed for invasion and metastasis of cancer cells. MLCK-dependent phosphorylation of cytoskeletal myosin II increases the metastatic potential of tumor cells, and MLCK-dependent cytoskeleton rearrangement modulates vascular endothelial barrier functions associated with angiogenesis, which is a critical step in cancer development ([@B18]). On the other hand, the metastatic potential of breast cancer cells is increased by the loss of MLCK ([@B28]). Changes in cell migration and adhesion are also characteristic early steps in inflammation but there are few reports of MLCK regulation of inflammatory cell migration.

MCLK in IBD
===========

Inflammatory bowel disease, including ulcerative colitis and Crohn's disease, is characterized by chronic gastrointestinal inflammation, and is associated with significant patient impairment and high treatment costs ([@B42]). Although the pathogenesis of IBD remains obscure, there is evidence that intestinal barrier dysfunction is the primary driver ([@B20]; [@B39]). Tight junction dysfunction leads to damage of the intestinal barrier, which permits passage of diverse pathogens ([@B25]). Tight junctions consist of transmembrane proteins such as occludins and claudins and peripheral membrane proteins, i.e., zonula occludens proteins ([@B54]). Tight junctions are located in the apicolateral region of endothelial cells and are bound to a perijunctional actomyosin ring. MLCK-induced phosphorylation of perijunctional actomyosin mediates tight junction loss, which can trigger the initiation and development of IBD. The expression and activity of MLCK is increased in human IBD and is associated with histological evidence of disease activity ([@B5]). Abnormal elevation of MLCK has also been observed in experimental colitis induced by gavage administration of dextran sulfate sodium or intracolonic administration of trinitrobenzenesulfonic acid ([@B50]; [@B64]).

MLCK Activation in IBD
----------------------

TNF-α is a proinflammatory cytokine that causes intestinal tight junction barrier dysfunction, which is central to IBD pathogenesis ([@B44]). In IBD, TNF receptor 2 (R2)-mediated signaling contributes to increased epithelial MLCK expression ([@B50]; [@B51]). In a recent report by [@B2], tight junction permeability of Caco-2 cell monolayers, in an *in vitro* model of intestinal epithelium, was increased by TNF-α activation of the ERK1/2 signaling pathway. Activation of the ERK1/2 pathway induced phosphorylation of ETS domain-containing transcription factor Elk-1. Activated Elk-1 then moved into the nucleus and bound to the MLCK promoter, finally resulting in epithelial MLCK expression. LIGHT (lymphotoxin-like inducible protein that competes with glycoprotein D for herpes virus entry on T cells) is a TNF core family member that is involved in the pathogenesis of human IBD ([@B29]), and in cultured epithelia, MLCK inhibition alleviated LIGHT-induced barrier loss, which suggested that LIGHT-induced epithelial barrier loss may depend on MLCK activation ([@B45]).

Increases in tight junction permeability through IL-1β--mediated increases in MLCK expression has been demonstrated in inflammatory diseases ([@B4]). In mesenchymal stem cell migration, IL-1β was shown to cause an increase in epithelial MLCK expression through activation of the PKCd/NF-κB pathway; it also stimulated MLCK activity via the PKCa/MEK/ERK signaling pathway ([@B31]).

IFN-γ has also been associated with activation of MLCK by promoting adhesion and internalization of commensal bacteria by epithelial MLCK-activated brush border fanning ([@B62]). However, as with LIGHT-mediated regulation of MLCK, further study of INF-γ-mediated regulation of MLCK is needed to determine if it is direct. Signaling pathways associated with regulation of MLCK are shown in **Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}**.

MLCK-Associated Signaling Pathways That Can Trigger IBD
-------------------------------------------------------

In IBD, MLCK-induced epithelial barrier dysfunction is triggered by two signaling pathways. Firstly, in the gut, the epithelium forms a barrier against pathogens in the lumen. Abnormal expression of MLCK in inflammatory gastrointestinal diseases leads to phosphorylation of myosin II regulatory light chain (MLC), contraction of the actomyosin ring and increased intestinal permeability ([@B67]). Thus, MLCK-dependent MLC phosphorylation is an essential mechanism underlying MLCK-induced epithelial barrier dysfunction. A second mechanism involves MLCK-stimulated upregulation of claudin-2 and occludin endocytosis ([@B50]; [@B25]). Increased expression of claudin-2 has been associated with intestinal epithelial barrier dysfunction ([@B22]; [@B30]), as well as decreased absorption, leak flux diarrhea, and inflammatory responses ([@B22]). Down-regulation of occludin in IBD decreases gastrointestinal permeability, which may disrupt the integrity of the barrier against a variety of pathogens ([@B69]).

Potential Pathological Role of Smooth Muscle MLCK in IBD
--------------------------------------------------------

Smooth muscle (sm) MLCK is transcribed from the same gene as epithelial MLCK. It is involved in the regulation of sm contraction, and variation of smMLCK content leads to motility disorders ([@B9]). The motility disorders secondarily cause abnormal growth of intestinal flora, which in turn aggravates the pathogenesis of intestinal inflammation ([@B10]; [@B61]). Whether there is a direct effect of smMLCK on inflammatory diseases needs further study.

MLCK Inhibitors with Potential Pharmaceutical Use
=================================================

Myosin light chain kinase has catalytic, inhibitory, and calmodulin-binding domains ([@B7]). The activity of the catalytic domain can be disclosed by partial tryptic digestion, and can be blocked by MLCK inhibitors ([@B33]; [@B7]). MLCK inhibitors act by competitive binding at or near the ATP-binding site on the MLCK molecule ([@B43]; [@B33]). MLCK has been extensively studied in sm, but is widely distributed in animal cells and tissues. Consequently, determining the activities of MLCK in other tissues is critical; MLCK inhibitors are good tools for this. MLCK inhibitors also have pharmacological potential as vasodilators and anti-inflammatory agents. Some MLCK inhibitors, their origins and evidence of pharmacological effect are listed in **Table [2](#T2){ref-type="table"}**.

###### 

Myosin light chain kinase inhibitors with potential pharmaceutical use.

  Name                 Source              Inhibited MLCK isoform   Disease or condition
  -------------------- ------------------- ------------------------ -------------------------------------------------------------------------------------------------
  ML-9                 Synthetic           nmMLCK, smMLCK           High blood pressure ([@B21]).
  ML-7                 Synthetic           nmMLCK, smMLCK           Heart ischemia/reperfusion injury ([@B32]; [@B73]), IBD ([@B14]), and atherosclerosis ([@B14]).
  K-252a               Microbial culture   nmMLCK, smMLCK           --
  KT592                Microbial culture   nmMLCK, smMLCK           --
  Wortmannin           Microbial culture   NmMLCK, smMLCK           --
  Quercetin            Natural source      SmMLCK                   Gut hyper motility ([@B72])
  Genistin             Natural source      smMLCK                   Intestinal hyper motility ([@B65])
  Wogonin              Natural source      nmMLCK                   Diseases associated with the development of both inflammatory and tumor ([@B23])
  Capsaicin            Natural source      smMLCK, nmMLCK           Intestinal motility disorder ([@B9])
  Salvianolic acid B   Natural source      NmMLCK                   IBD ([@B64])
  Lithium              Natural source      smMLCK                   Intestinal hyper motility ([@B52])

The diseases or conditions in which MLCK inhibition and/or MLCK inhibitors have shown a therapeutic effect are discussed in "Diseases and condition." nmMLCK, non-muscle MLCK; smMLCK, smooth muscle MLCK

.

ML-9 and ML-7
-------------

ML-9 \[1-(5-chloronaphthalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine\] is a classical MLCK inhibitor (IC~50~ = 3.8 μM), which was found to inhibit both Ca^2+^-calmodulin--dependent and -independent smMLCK ([@B43]; [@B48]). Both ML-9 and its synthetic derivatives are good selective inhibitors of smMLCK ([@B24]). ML-9 has been shown to reduce intraocular pressure in rabbit eyes ([@B21]).

Another MLCK inhibitor, ML-7 \[1-(5-iodonaphthalene-1-sulphonyl) 1H-hexahydro 1, 4-diazepine hydrochloride\], is a membrane-permeable agent ([@B48]). Both ML-9 and ML-7 are naphthalene sulfonamide derivatives ([@B48]). ML-7 inhibition is more than 30-fold more potent than that of ML-9 (IC~50~ = 300 nM) ([@B48]). However, compared with ML-9, specific MLCK inhibition of smMLCK and other MLCK isoforms may be less potent ([@B43]). Beneficial effects of ML-7 has been shown in many conditions including heart ischemia/reperfusion injury ([@B32]; [@B73]), IBD ([@B14]), and atherosclerosis ([@B14]).

Microbial Product Inhibitors of MLCK
------------------------------------

K-252a, a microbial alkaloid purified from microbial cultures, is a non-selective inhibitor of MLCK ([@B38]) as well as other protein kinases including protein kinase C and some cyclic nucleotide-dependent protein kinases ([@B38]). KT592 is a derivative of K-252a with increased selectivity. Wortmannin, isolated and purified from the fungal strain *Talaromyces wortmannin* KY12420, is another microbial product inhibitor of MLCK ([@B38]), It has been shown to decrease secretory responses in rat adrenal medullary cells through inhibition of MLCK ([@B59]) and to have antifungal, hemorrhagic, and anti-inflammatory activity that may not be related to inhibition of MLCK ([@B38]). The potential pharmacological effects of these inhibitors warrant further study.

Naturally Occurring Potential Inhibitors of MLCK
------------------------------------------------

As shown in **Table [2](#T2){ref-type="table"}**, some naturally occurring bioactive constituents may be inhibitors of MLCK. In an *in vitro* system including purified myosin and MLCK, quercetin inhibited myosin phosphorylation. The inhibition can be blocked by the MLCK inhibitor ML-7, indicating that quercetin may be a direct MLCK inhibitor ([@B72]). In an animal model of gut motility disorder, capsaicin administration significantly decreased MLCK expression, which also implicates MLCK as a target for inhibition by capsaicin ([@B9]). The inhibition in response to salvianolic acid B may be indirect; other signaling is involved. Salvianolic acid B decreases MLCK expression by upregulation of microRNA1 ([@B64]). Upregulation of microRNA-374a, microRNA-155, miR-520c-3p, and miR-1290 has also been found to reduce MLCK expression in various tissues ([@B1]; [@B60]). Naturally occurring bioactive compounds that act indirectly through microRNAs are an alternative inhibition pathway. However, disease-specific pharmacological experiments are needed to confirm the effects of potential naturally occurring inhibitors of MLCK.

Summary
=======

This review summarizes the evidence for a role of MLCK in inflammatory diseases, especially IBD. Abnormal expression of MLCK is involved in diverse pathological events, mainly by causing cytoskeletal changes that disrupt epithelial barrier function. The effect of anti-MLCK agents in specific inflammatory diseases depends on the extent to which endothelial function is involved. Prevention of treatment-related side effects is a key consideration because MLCK is abundantly expressed in many tissues. Consideration of two aspects of selectivity helps to anticipate and prevent side effects of MLCK inhibitors. First is the selective inhibition of MLCK and other protein kinases such as protein kinase C and cyclic nucleotide-dependent protein kinase; the other is selective inhibition of the different MLCK isoforms such as smMLCK and nmMLCK. Potential anti-MLCK pharmaceutical agents offer a novel insight into the treatment of inflammatory diseases that differs from traditional anti-inflammatory therapy.
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**Mechanisms underlying MLCK-induced regulation of the endothelial barrier function are shown**. Solid arrows indicate direct interaction and dotted arrows indicate indirect interactions.
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